蒙药额力根II号对肝纤维化大鼠的保护作用研究

doi:10.3969/j.issn.1672-5069.2021.02.008

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 180-183.doi: 10.3969/j.issn.1672-5069.2021.02.008

蒙药额力根II号对肝纤维化大鼠的保护作用研究

苏琪皓, 任丽梅, 姜凤霞, 武金宝, 江振宇

014030 内蒙古自治区包头市包头医学院第二附属医院消化科(苏琪皓,任丽梅,武金宝,江振宇);
包头市蒙中医院(姜凤霞)

收稿日期:2020-03-20 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 姜凤霞,E-mail:1943573987@qq.com
作者简介:苏琪皓,男,28岁,硕士研究生,住院医师。主要从事消化内镜诊断与治疗学研究。E-mail:1826312052@qq.com 共同第一作者:任丽梅,女,46岁,主任医师。主要从事消化科疾病的诊断与治疗。E-mail:rlm6711@163.com
基金资助:
包头市医药卫生科技计划项目(编号:VSJJ2018096);包头医学院自然科学类扬帆计划项目(编号:BYJJ-YF201743)

Protective effect of Mongolian medicine Erligen II on liver fibrosis in rats

Su Qihao, Ren Limei, Jiang Fengxia, et al

Department of Gastroenterology, Second Affiliated Hospital, Baotou Medical College, Baotou 014030, Inner Mongolia Automonous Region, China

Received:2020-03-20 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的观察蒙药额力根II号对CCl₄诱导的肝纤维化大鼠的保护作用。方法随机将58只SD大鼠分为对照组、模型组、蒙药额力根II号小、中、大剂量干预组,制备CCl₄肝纤维化模型,并给予蒙药干预。观察肝组织病理学变化,并采用免疫组化法检测肝组织α-SMA、I型胶原和III型胶原的表达。结果与模型组比,中剂量药物处理组动物血清ALT、AST和透明质酸(HA)水平显著降低(P＜0.05),大剂量药物处理组血清ALT、AST、TBIL、HA、III型前胶原(PIIINP)和IV型胶原(CIV)水平降低更显著(P＜0.05);对照组、中和大剂量药物干预组肝组织α-平滑肌肌动蛋白表达水平分别为(0.0±0.0)、(4.9±1.0)、(3.4±0.9),显著低于模型组【(6.1±1.2),P＜0.05】,III型胶原蛋白分别为(2.4±1.3)、(5.0±2.4)和(3.7±1.8),显著低于模型组【(6.4±2.4),P＜0.05】;对照组和大剂量干预组肝组织I型胶原蛋白分别为(2.1±0.2)和(3.3±1.0),显著低于模型组【(6.0±2.5),P＜0.05】;与模型组比,中和大剂量药物处理组大鼠肝组织纤维化程度显著改善。结论蒙药额力根II号对CCl₄诱导的肝纤维化大鼠具有保护作用,其机制可能与抑制了肝星状细胞活化,减少了细胞外基质的合成有关。

关键词: 肝纤维化, 蒙药额力根II号, α-SMA, 胶原蛋白, 大鼠

Abstract: Objective The purpose of this study was to observe the effect of Mongolian medicine Erligen II on carbon tetrachloride-induced liver fibrosis in rats and explore its possible acting mechanism. Method 58 male SD rats were randomly divided into control, model, low-, moderate- and large-dose of Mongolian medicine Erligen II-intervened groups, and the fibrosis model was established by 40% CCl₄ olive oil solution injection for 8 weeks. Four weeks after modeling, the rats in model group were given intragastrically once daily at different dose of Erligen- II , and in the control group were given the same dose of normal saline for 5 weeks. The pathological changes were observed by HE and Masson staining of liver tissue, and the expression of α-SMA, collagen I and collagen III in liver tissue were detected by immunohistochemistry.Results Serum levels of ALT, AST and HA in moderate dose of Erligen- II-intervened group decreased greatly compared to those in model (P <0.05) , and serum levels of ALT, AST, bilirubin, HA, PIIINP and CIV in large dose of Erligen- II-intervened group decreased significantly compared to those in the model (P<0.05) ; the hepatic expression of α-SMA in control, moderate and large dose of Erligen- II were (0.0±0.0), (4.9±1.0) and (3.4±0.9),significantly weaker than 【(6.1±1.2),P＜0.05】 in model, and that of collagen III were (2.4±1.3), (5.0±2.4) and (3.7±1.8), significantly weaker than 【(6.4±2.4), P＜0.05】 in the model; the hepatic expression of collagen I in the control and in large dose of Erligen- II were (2.1±0.2) and (3.3±1.0), significantly weaker than 【(6.0±2.5), P＜0.05】 in the model; the hepatic fibrosis improved greatly in moderate and large dose Erligen- II groups compared to in the model.Conclusions Mongolian medicine Erligen II has a protective effect on CCl₄-induced liver fibrosis in rats, which might be related to the inhibition of HSC activation and reduction of ECM synthesis.

Key words: Liver fibrosis, Mongolian medicine, Erligen II, α-SMA, Collagen I, Collagen III, Rats

苏琪皓, 任丽梅, 姜凤霞, 武金宝, 江振宇. 蒙药额力根II号对肝纤维化大鼠的保护作用研究[J]. 实用肝脏病杂志, 2021, 24(2): 180-183.

Su Qihao, Ren Limei, Jiang Fengxia, et al. Protective effect of Mongolian medicine Erligen II on liver fibrosis in rats[J]. Journal of Practical Hepatology, 2021, 24(2): 180-183.

参考文献

[1] Atta H M . Reversibility and heritability of liver fibrosis: Implications for research and therapy. World J Gastroenterol, 2015, 21(17):5138-5148.
[2] Jiménez JV,Carrillo-Pérez DL,Rosado-Canto R,et al.Electrolyte and acid-base disturbances in end-stage liver disease:A physiopathological approach. Dig Dis Sci,2017,62(8):1855-1871.
[3] Schumacher J D,Guo G L. Regulation of hepatic stellate cells and fibrogenesis by fibroblast growth factors. Biomed Res Int,2016,2016:1-8.
[4] Feng J,Chen K,Xia YJ, et al.Salidroside ameliorates autophagy and activation of hepatic stellate cells in mice via NF-κB and TGF-β1/Smad3 pathways.Drug Design Develop Ther,2018,12:1837-1853.
[5] Deng X H,Xing X Y,Li G,et al.Th1/Th2 imbalance in ischemia-reperfusion injury and the application prospects of traditional Chinese medicine with multi-target effect. Chin Pharmacol Bull,2015,31(9):1185-1189.
[6] 陆伦根,尤红,谢渭芬,等.肝纤维化诊断及治疗共识(2019年).实用肝脏病杂志,2019,22(6):793-803.
[7] Yang Z,Zhang X,Yang L,et al.Protective effect of anoectochilus roxburghii polysaccharide against CCl4-induced oxidative liver damage in mice. Int J Biol Macromolec,2017,96:442-450.
[8] 徐飞,李伟荣.黄芪甲苷对CCL4所致肝损伤大鼠的保护作用.实用肝脏病杂志,2019,22(6):808-811.
[9] Rong X, Yang Y, Zhang G. Antler stem cells as a novel stem cell source for reducing liver fibrosis. Cell Tissue Res, 2020,379(1):195-206.
[10] Ishak K,Baptista A,Bianchi L,et al.Histological grading and staging of chronic hepatitis.J Hepatol,1995,22(6):696-699.
[11] Zhu YP,Bu SX.New research progress of pathogenesis of hepatic fifibrosis. Chin Hepatol,2016,21(5):401-403.
[12] Jiang H,Qin XJ, Li WP,et al. Effects of shu gan jian pi formula on rats with carbon tetrachloride-induced liver fibrosis using serum metabonomics based on gas chromatography-time of flight mass spectrometry. Mol Med Rep,2017,16(4):3901-3909.
[13] Weiskirchen T. An update on the recent advances in antifibrotic therapy. Expert review of gastroenterology & amp. Hepatology,2018,12(11):1143-1152.
[14] Omar Abdulhameed A, Mohammad Kowser M, Raman V. Drug metabolism in the liver. Clin Liver Dis,2017,21(1):1-20.
[15] Halenova T I,Vareniuk I M,Roslova N M,et al.Hepatoprotective effect of orally applied water-soluble pristine C60 fullerene against CCl4-induced acute liver injury in rats. RSC Adv,2016,6(102):100046-100055.
[16] Atsushi H, Takashi K, Masatoshi K,et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer,2017,6(3):204-215.
[17] Khoury T,Chen S,Abu Rmeileh A,et al.Acute liver injury induced by levetiracetam and temozolomide co-treatment.Dig Liver Dis,2017,49(3):297-300.
[18] Zhang KF, Gao Y,Zhong ML, et al. Hepatoprotective effects of dicliptera chinensis polysaccharides on dimethylnitrosamine-induced hepatic fibrosis rats and its underlying mechanism. J Ethnopharmacol,2016,179:38-44.
[19] 蔡乐斌,陶娜.聚乙二醇干扰素α-2a联合阿德福韦酯治疗HBeAg阳性慢性乙型肝炎患者疗效及对血清细胞因子和肝纤维化指标的影响.实用肝脏病杂志,2016, 19(5): 532-535.
[20] Ping W,Jiangtao LI. The clinical observation on spiral CT perfusion imaging in patients with hepatic fibrosis. China Med Herald,2010,7(9):15-17.

蒙药额力根II号对肝纤维化大鼠的保护作用研究

Protective effect of Mongolian medicine Erligen II on liver fibrosis in rats

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭婕, 李弼民, 雷宇鹏. 四氯化碳诱导的肝纤维化小鼠肝组织和HSC-T6细胞NOX4基因及其蛋白表达的变化[J]. 实用肝脏病杂志, 2021, 24(3): 319-322.
[2]	都庆国, 陆建文, 王建华, 龙延滨, 薛飞. 生长抑素通过抑制内质网应激反应减轻肝纤维化小鼠肝损伤研究[J]. 实用肝脏病杂志, 2021, 24(2): 172-175.
[3]	荣海芳, 王立国. 胆总管结扎诱导大鼠肝肺综合征模型的建立初步研究[J]. 实用肝脏病杂志, 2021, 24(2): 176-179.
[4]	代海峰, 王甜, 雷迅, 蔡佳, 黄文祥. 应用瞬时弹性成像技术联合APRI和AAR指数评估慢性乙型肝炎患者肝纤维化临床价值研究[J]. 实用肝脏病杂志, 2021, 24(2): 196-199.
[5]	荣爱梅, 张超, 吴慧丽. 西罗莫司对高脂饮食诱导的NAFLD大鼠外周血Treg/Th17细胞的影响[J]. 实用肝脏病杂志, 2021, 24(1): 10-13.
[6]	吴冬秋, 崔丽华, 熊峰, 邬政宏. 血清IL-34联合超声弹性成像诊断慢性乙型肝炎患者肝纤维化的效能分析[J]. 实用肝脏病杂志, 2021, 24(1): 23-26.
[7]	刘瑞清(综述), 袁小澎(审校). 缺氧诱导因子-1α参与肝纤维化形成机制研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 145-148.
[8]	宋叶雨(综述), 范建高(审校). 少肌性肥胖合并脂肪性肝病的诊断与治疗[J]. 实用肝脏病杂志, 2021, 24(1): 149-152.
[9]	李伟, 郭春霞, 刘苏南. 白藜芦醇对部分肝切除术大鼠肝再生和肝组织NK细胞活性的影响^*[J]. 实用肝脏病杂志, 2020, 23(6): 785-788.
[10]	韩冬, 陆洋, 柏根基, 史昭菲. 超声声速匹配联合磁共振弥散加权成像技术评估慢性乙型肝炎患者肝纤维化程度价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 789-792.
[11]	柳迪, 董鑫, 杨建军, 吴云英, 张龙方, 刘妍. 瞬时弹性成像联合门静脉血流动力学指标诊断慢性乙型肝炎患者肝纤维化意义探讨^*[J]. 实用肝脏病杂志, 2020, 23(6): 797-800.
[12]	唐平阳, 王洁冰, 张晓兰, 唐启群. 血清HBeAg阴性慢性乙型肝炎患者APRI、FIB-4和血清TGF-β1水平变化^*[J]. 实用肝脏病杂志, 2020, 23(6): 801-804.
[13]	崔璐瑶, 苑喜微, 刘领弟, 张莹, 赵文, 赵丹丹, 杨杨, 南月敏. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 809-812.
[14]	王雨, 王楠, 刘媛媛, 李永勤, 王巧侠, 付建军. 草质素对非酒精性脂肪性肝炎大鼠肝脂肪变和肝内氧化应激的影响[J]. 实用肝脏病杂志, 2020, 23(5): 626-629.
[15]	张浩, 常建东, 陈小燕. 超声弹性成像结合血清学指标诊断慢性乙型肝炎患者肝纤维化价值评价[J]. 实用肝脏病杂志, 2020, 23(5): 642-645.